LANCASTER GENERAL HOSPITAL BECOMES WORLD’S FIRST HOSPITAL TO INTEGRATE EMR WITH PCA INFUSION PUMP TO DRIVE SAFETY AND TRANSPARENCY IN PATIENT PAIN MANAGEMENT
—Advanced technology from Hospira and Epic enables LGH to bring next-generation infusion safety to patients—
LANCASTER, Pa., and LAKE FOREST, Ill., Dec. 1, 2016—Lancaster General Health (LG Health) has become the world's first health system to integrate a patient-controlled analgesia (PCA) infusion pump with its electronic medical record (EMR) system. The integration is powered by Hospira's LifeCare PCA® 7.0 infusion system and EMR provider Epic Systems. This marks the first time that PCA and EMR technologies have been connected in a clinical setting.
Patients at Lancaster General Hospital and Women & Babies Hospital will now benefit from this seamlessly integrative pain management technology. PCA pumps, most often used in the hospital after surgery, allow patients to self-administer pain medicine, such as important but high-risk narcotics, within a set amount determined by the physician.
"This innovative technology will enhance patient safety, efficiently document patient data and provide nursing staff more time to focus on the needs of hospital patients receiving PCA therapy," said Jan Bergen, President & CEO, LG Health. "After extensive testing, we are proud to be the first health system to successfully integrate PCA pumps with our EMR, as we recognize the benefits it brings to our patients and clinicians."
Considered the next evolution in smart pump connectivity, PCA-EMR integration has been highly anticipated in the medical community. This achievement marks yet another technology milestone for LG Health, which has long been a pioneer in smart pump connectivity. LG Health first integrated a smart pump with an EMR in 2008, and has pumps integrated with Hospira and Epic technology live within its inpatient, emergency department, outpatient, pediatric, NICU and oncology facilities across the health system. Additionally, as PCA technology deals with the administration of high-risk narcotics, integrating with the EMR helps increase transparency for clinicians when transitioning patients from intravenous to oral medications.
PCA-EMR integration presents next-generation benefits to patients. Hospira LifeCare PCA 7.0, the first PCA pump on the market to offer EMR integration capabilities, can be automatically programmed with the validated medication order direct from the Epic EMR, and streamlines documentation of infusion data into the Epic system to help improve the safety and efficiency of pain management medication therapy. Additionally, it is the first and only PCA pump to offer integrated bar code identification of prefilled and pharmacy-filled drug vials, substantially reducing the potential for drug and concentration errors at the bedside.
"The path to meaningful progress in healthcare technology starts and ends with the patient," said Julie Sawyer Montgomery, President, Hospira Infusion Systems. "This milestone with Lancaster General Health and Epic supports Hospira's dedication to addressing unsolved patient challenges through the continual development of innovative technology for IV therapy."
Epic's integrated, interoperable platform offers connections to hundreds of third-party offerings. "Congratulations to Lancaster General Health for being the first to deploy this life-saving technology. They are a pioneer in this important aspect of increasing patient safety, and we look forward to seeing results with additional health systems soon." said Carl Dvorak, President, Epic.
This announcement comes on the heels of Hospira officially launching LifeCare PCA 7.0 in May. Hospira has focused on advancing interoperability for many years. In support of its global device strategy to deliver new technologies, Hospira has launched four new infusion system products in the last 24 months.
About Lancaster General Health
Lancaster General Health (LG Health), a member of the University of Pennsylvania Health System (Penn Medicine), is a 689-licensed bed not-for-profit health system with a comprehensive network of care encompassing Lancaster General Hospital (LGH), Women & Babies Hospital and the Lancaster Rehabilitation Hospital (in partnership with Kindred Healthcare). Our membership in Penn Medicine brings together the strengths of a world-renowned, not-for-profit academic medical center and a nationally recognized, not-for-profit community healthcare system.
Outpatient services are provided at the Downtown and Suburban pavilions, along with additional outpatient centers and Express and Urgent Care locations throughout the region. Lancaster General Health Physicians is a network of nearly 300 primary-care and specialty physicians, at more than 40 offices throughout the region. Pennsylvania College of Health Sciences is a private, co-educational, Middle States-accredited four-year college offering a variety of associate and baccalaureate degree and certification programs in healthcare.
Designated a Magnet hospital for nursing excellence four consecutive times, LGH has been recognized regionally and nationally for clinical excellence and patient safety; and ranked nationally by U.S. News & World Report as one of the nation's best hospitals in 2016-17 in two specialties.
Hospira, a Pfizer company, is a leading provider of infusion technologies. The company's focused infusion systems portfolio features I.V. solutions, proven, innovative smart pumps, and pain management and safety software technology designed to help meet clinical, safety and workflow goals. Learn more at www.hospira.com.
Lancaster General Health
Hospira, a Pfizer company
PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 30, 2016. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information regarding Hospira's LifeCare PCA® 7.0 infusion system, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial impact of LifeCare PCA® 7.0 infusion system; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.